Drug Research
United States-Switzerland Strike A Drug Inspection Accord
The US and Switzerland have agreed to a Mutual Recognition Agreement (MRA) on pharmaceutical Good Manufacturing Practices (GMP).
The US Food and Drug Administration (FDA) and the Swiss Agency for Therapeutic Products (Swissmedic) will be able to utilize each other's...
Drug Research
5 FDA Announcements To Pay Attention To In The 2023 Q1
The biotechnology sector had a decline in 2022 that went beyond just falling stock prices. Additionally, only 37 new drugs were approved by the FDA's primary review office last year, the lowest number since 2016.
Yet there is cause for...
Drug Research
Watch Out For These Potential Best-Seller Drugs In 2023
In the 70 pharmaceuticals featured in Clarivate Plc's Drugs to WatchTM 2023 study, comprising potential blockbuster drugs, the bulk were found to be personalised medicines.
The report provides a predicted analysis of new medication launches or major indication launches in...
Drug Research
Study Reveals That Gut Microbiome Is Crucial In Parkinsons
Metagenomics, the study of genetic material extracted directly from the stool microbiomes of people with PD and neurologically healthy control participants, was used by researchers at the University of Alabama at Birmingham in the US.
The gut microbiome is engaged...
Drug Research
The AMR Action Fund Invests in BioVersys in Fight Against Drug-Resistant Bacteria
The AMR Action Fund, a public-private partnership investing in biotech companies developing antimicrobials, has invested in BioVersys AG, a clinical-stage company based in Basel, Switzerland. The transaction marks the Fund's first investment in Europe and is an important step...
Drug Research
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
AbbVie and Immunome, Inc., a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced a worldwide collaboration and option agreement directed to the discovery of up to 10 novel...
Drug Research
BMS, Dragonfly Enter Exclusive License for Sixth TriNKET Immunotherapy Candidate
Bristol Myers Squibb has exercised its option under a research collaboration with Dragonfly Therapeutics, Inc, to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate, bringing the total drug candidates licensed by BMS to seven including...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read